Vironexis Biotherapeutics Inc.
Vironexis Biotherapeutics Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, acute biphenotypic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, mixed phenotype acute leukemia, neoplasm, non-Hodgkin lymphoma, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-08-06 | NCT06533579 | |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | HER2 Expressing Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-07-28 | NCT07192432 |